Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Peterson, D E ^a   Bensadoun, R J ^b   Roila, F ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BENZYDAMINE; CHLORHEXIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MESALAZINE; METHOTREXATE; MORPHINE; NAVELBINE; OLSALAZINE; OXALIPLATIN; PACLITAXEL; PALIFERMIN; PENTOXIFYLLINE; PLATINUM COMPLEX; PREDNISONE; RANITIDINE; SALAZOSULFAPYRIDINE; SUCRALFATE; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; COLON CANCER; COLORECTAL CANCER; CRYOTHERAPY; DIARRHEA; EPIGASTRIC PAIN; EUROPE; GASTROINTESTINAL MUCOSA; GOOD CLINICAL PRACTICE; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYDRATION; LOW LEVEL LASER THERAPY; LUNG CANCER; MEDICAL ASSESSMENT; MEDICAL SOCIETY; MOUTH HYGIENE; MOUTH MUCOSA; MOUTH PAIN; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PATIENT CONTROLLED ANALGESIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCTITIS; RECOMMENDED DRUG DOSE; RISK FACTOR;

CRYOTHERAPY; DRUG THERAPY; EUROPE; HUMANS; INCIDENCE; MUCOSITIS; RADIOTHERAPY; RISK FACTORS;

EID: 77954330031     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq197     Document Type: Article

References (24)

1. Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100(9 Suppl): 2026-2046.
2. Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced mucosal injury. Cancer 2004; 100(9 Suppl): 1995-2025.
3. Jones JA, Avritscher EB, Cooksley CD et al. Epidemiology of treatment associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006; 14: 505-515.
4. Peterson DE, Keefe DM, Hutchins RD et al. Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Support Care Cancer 2006; 14: 499-504.
5. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-831.
6. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007; 5(9 Suppl 4): 3-11.
7. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
8. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086.
9. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
10. Bensadoun RJ, Bénézery K, Dassonville O et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006; 64: 983-994.
11. Elting LS, Keefe DM, Sonis ST et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 2008; 113: 2704-2713.
12. Thyss A, Milano G, Renee N et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986; 16: 64-66.
13. Schneider M, Etienne MC, Milano G et al. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 1995; 13: 1656-1662.
14. Passardi A, Maltoni R, Milandri C et al. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: Drug sequencing based on clinical modelling studies. Oncology 2007; 72: 118-124.
15. Rask C, Albertioni F, Bentzen SM et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-a logistic regression analysis. Acta Oncol 1998; 37: 277-284.
16. Ruiz-Argüelles GJ, Coconi-Linares LN, Garcés-Eisele J et al. Methotrexateinduced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology 2007; 12: 387-391.
17. Rosen LS, Abdi E, Davis ID et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracilbased chemotherapy. J Clin Oncol 2006; 24: 5194-5200.
18. Peterson DE, Barker NP, Akhmadullina LI et al. Phase II, randomized, doubleblind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol 2009; 27: 4333-4338.
19. Worthington HV. Clarkson JE and Eden OB. Cochrane Database Syst Rev 2007; (issue4): CD000978.
20. Lutgens LC, Blijlevens NM, Deutz NE et al. Monitoring myeloablative therapyinduced small bowel toxicity by serum citrulline concentration: A comparison with sugar permeability tests. Cancer 2005; 103: 191-199.
21. Tooley KL, Howarth GS, Butler RN. Mucositis and non-invasive markers of small intestinal function. Cancer Biol Ther 2009; 8: 753-758.
22. Clark JW. Molecular targeted drugs and growth factor receptor inhibitors. In Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice, 4th edition. Philadelphia: Lippincott, Williams & Wilkins 2006; 641-665.
23. Keefe DM, Gibson RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 2007; 15: 483-490.
24. Sankhala K, Mita A, Kelly K et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009; 4: 135-142.